EVOK(Delisted)
Evoke Pharma·NASDAQ
--
--(--)
6.85 / 10
Outperform
Fund flow scores 6.85/10 (positive), with inflow across most categories except Medium. No analyst data (ana_eval=-1). Overall and institutional trends are bullish, though Medium inflow headwinds require monitoring.
Fund Flow Rating
What is the analyst consensus for EVOK?
- EVOK holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.85/10 (Outperform).
